Skip to content

Sira vyadha (vein section) in pain management of Sciatica

Evaluation of efficacy of siravyadha in pain management of vata-kaphaja gridhrasi on selected inflammatory bio-markers(Substance-P,TNF-alpha,IL-6)-An open label clinical trial - NIL

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061213
Enrollment
15
Registered
2024-01-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G55- Nerve root and plexus compressionsin diseases classified elsewhere

Interventions

None listed

Sponsors

Dr M Puneet
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects fulfilling Diagnostic criteria of sciatica Subjects with either Sex and Age between 20 – 60 years Yogya for Sira vyadha Subjects with normal CT,BT and No clinical signs of Anaemia.

Exclusion criteria

Exclusion criteria: Ayogya for Sira vyadha Subjects with H/O spinal tuberculosis/lesion/ injury, HIV I&II, HbsAG infections, severe anaemia or any other chronic illness (Like Diabetes,Hypertension etc) and pregnancy Subjects with Surgical History for back pain Subjects with K/C/O bleeding disorders

Design outcomes

Primary

MeasureTime frame
Visual analogue scale and Verbal descriptive scaleTimepoint: Before treatment and Immediately after treatment and after 24hrs on 7th day

Secondary

MeasureTime frame
Ruk Toda Sthambha Saktikshepananigrahath Chimchimayana SLR FLACC SCALE Oswestry low back disability index Range of motion Substance-P tnf-alpha IL-6Timepoint: Before treatment and Immediately after treatment and after 24hrs on 7th day

Countries

India

Contacts

Public ContactDr Pradeep S Shindhe

KAHER Shri B M K Ayurveda Mahavidyalaya and Medical Research center Shahapur Belagavi

pshindhe@gmail.com9986331357

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026